Literature DB >> 29244615

Risk assessment for Japanese encephalitis vaccination.

Lance Turtle1,2,3, Carolyn Driver4.   

Abstract

Japanese encephalitis (JE) is the most commonly diagnosed viral encephalitis in Asia. JE is caused by a virus called JE virus (JEV), a member of the genus Flavivirus, family Flaviviridae, and is transmitted by Culex mosquitoes. Neutralising antibody to JEV protects against JE, and can be induced by vaccination. JE is a potential threat to travellers to endemic areas, which are most of South and Southeast Asia and some Pacific Islands. The risk of JE can be expected to increase with increasing mosquito exposure and time spent in regions and seasons of active transmission. JE is very rare in travellers, but mortality is high, around 1 in 3, and there is a high rate of lasting neurological damage. JE can therefore be a profoundly life changing event for a traveller. Travellers and their healthcare providers need to balance the low risk of disease against the very high severity of disease if it does occur. In order to make an informed decision, the severity of JE disease should be carefully explained to travellers to Asia.

Entities:  

Keywords:  Japanese encephalitis; risk assessment; travellers; vaccination

Mesh:

Substances:

Year:  2017        PMID: 29244615      PMCID: PMC5791557          DOI: 10.1080/21645515.2017.1380756

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  32 in total

1.  Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials.

Authors:  Joseph Torresi; Karen McCarthy; Emmanuel Feroldi; Claude Méric
Journal:  Vaccine       Date:  2010-10-08       Impact factor: 3.641

2.  Viral etiology of acute childhood encephalitis in Beijing diagnosed by analysis of single samples.

Authors:  Y Xu; G Zhaori; S Vene; K Shen; Y Zhou; L O Magnius; B Wahren; A Linde
Journal:  Pediatr Infect Dis J       Date:  1996-11       Impact factor: 2.129

3.  Short-Term Immunogenicity and Safety of an Accelerated Pre-Exposure Prophylaxis Regimen With Japanese Encephalitis Vaccine in Combination With a Rabies Vaccine: A Phase III, Multicenter, Observer-Blind Study.

Authors:  Tomas Jelinek; Gerd D Burchard; Sebastian Dieckmann; Silja Bühler; Maria Paulke-Korinek; Hans D Nothdurft; Emil Reisinger; Khaleel Ahmed; Dietrich Bosse; Seetha Meyer; Marco Costantini; Michele Pellegrini
Journal:  J Travel Med       Date:  2015-05-22       Impact factor: 8.490

4.  Japanese encephalitis in north Queensland, Australia, 1998.

Authors:  J N Hanna; S A Ritchie; D A Phillips; J M Lee; S L Hills; A F van den Hurk; A T Pyke; C A Johansen; J S Mackenzie
Journal:  Med J Aust       Date:  1999-06-07       Impact factor: 7.738

5.  Kinetics of IgM and IgG responses to Japanese encephalitis virus in human serum and cerebrospinal fluid.

Authors:  D S Burke; A Nisalak; M A Ussery; T Laorakpongse; S Chantavibul
Journal:  J Infect Dis       Date:  1985-06       Impact factor: 5.226

6.  Seizures and raised intracranial pressure in Vietnamese patients with Japanese encephalitis.

Authors:  Tom Solomon; Nguyen Minh Dung; Rachel Kneen; Le Thi Thu Thao; Mary Gainsborough; Ananda Nisalak; Nicholas P J Day; Fenella J Kirkham; David W Vaughn; Shelagh Smith; Nicholas J White
Journal:  Brain       Date:  2002-05       Impact factor: 13.501

7.  Epidemiology of the arthropod-borne encephalitides.

Authors:  J A MILES
Journal:  Bull World Health Organ       Date:  1960       Impact factor: 9.408

8.  First indigenous transmission of Japanese Encephalitis in urban areas of National Capital Territory of Delhi, India.

Authors:  Roop Kumari; Kaushal Kumar; Ashok Rawat; GirRaj Singh; Narendra K Yadav; Lakhbir S Chauhan
Journal:  Trop Med Int Health       Date:  2013-06       Impact factor: 2.622

9.  Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial.

Authors:  E Tauber; H Kollaritsch; M Korinek; P Rendi-Wagner; B Jilma; C Firbas; S Schranz; E Jong; A Klingler; S Dewasthaly; C S Klade
Journal:  Lancet       Date:  2007-12-01       Impact factor: 79.321

Review 10.  Japanese encephalitis virus infection.

Authors:  Michael J Griffiths; Lance Turtle; Tom Solomon
Journal:  Handb Clin Neurol       Date:  2014
View more
  5 in total

1.  EGFR Activation Impairs Antiviral Activity of Interferon Signaling in Brain Microvascular Endothelial Cells During Japanese Encephalitis Virus Infection.

Authors:  Ya-Ge Zhang; Hao-Wei Chen; Hong-Xin Zhang; Ke Wang; Jie Su; Yan-Ru Chen; Xiang-Ru Wang; Zhen-Fang Fu; Min Cui
Journal:  Front Microbiol       Date:  2022-06-30       Impact factor: 6.064

2.  Molecular interaction of the antiviral compound CW‑33 and its analogues with the NS2B‑NS3 protease of the Japanese encephalitis virus.

Authors:  Kuan-Chung Chen; Yu-Fong Lin; An-Cheng Huang; Jing-Yang Gao; Cheng-Wen Lin; Jin-Cherng Lien
Journal:  Int J Mol Med       Date:  2019-02-27       Impact factor: 4.101

Review 3.  Review of Emerging Japanese Encephalitis Virus: New Aspects and Concepts about Entry into the Brain and Inter-Cellular Spreading.

Authors:  Luis Filgueira; Nils Lannes
Journal:  Pathogens       Date:  2019-07-26

4.  Generation and characterization of Japanese encephalitis virus expressing GFP reporter gene for high throughput drug screening.

Authors:  Zhe-Rui Zhang; Hong-Qing Zhang; Xiao-Dan Li; Cheng-Lin Deng; Zhen Wang; Jia-Qi Li; Na Li; Qiu-Yan Zhang; Hong-Lei Zhang; Bo Zhang; Han-Qing Ye
Journal:  Antiviral Res       Date:  2020-08-01       Impact factor: 5.970

5.  'More than devastating'-patient experiences and neurological sequelae of Japanese encephalitis§.

Authors:  Lance Turtle; Ava Easton; Sylviane Defres; Mark Ellul; Begona Bovill; Jim Hoyle; Agam Jung; Penny Lewthwaite; Tom Solomon
Journal:  J Travel Med       Date:  2019-10-14       Impact factor: 8.490

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.